Mepsevii

Vestronidase alfa, the active ingredient in Mepsevii, is an enzyme replacement therapy presented as an intravenous solution for intravenous use. It replaces the deficient beta‑glucuronidase enzyme and is indicated for patients with mucopolysaccharidosis type VII (Sly disease), a rare lysosomal storage disorder.

GNH USA supplies Mepsevii as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring quality assurance, cold‑chain logistics and regulatory compliance for global distribution.

Mepsevii is used in the lysosomal storage disease pathway to treat the underlying enzyme deficiency.

Mucopolysaccharidosis type VII (Sly disease): reduces glycosaminoglycan accumulation and helps improve clinical manifestations such as organomegaly, skeletal abnormalities, and respiratory function.

Mepsevii may be associated with several adverse reactions observed during clinical use.

Common Side Effects: - Infusion‑related reactions (e.g., chills, fever, flushing) - Headache - Nausea - Fatigue

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity - Hepatic enzyme elevation (ALT/AST increase) - Thrombocytopenia or bleeding disorders

Before initiating Mepsevii, clinicians should consider the following precautions.

Infusion monitoring: observe patients during and after infusion for signs of hypersensitivity. Liver function: assess baseline hepatic enzymes and monitor periodically. Immunogenicity: evaluate for anti‑drug antibodies that may affect efficacy. Pregnancy and lactation: safety has not been established; use only if potential benefit justifies risk. Known hypersensitivity: avoid in patients with documented allergy to vestronidase alfa or any excipients. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mepsevii can interact with other medicines, requiring attention to the following.

Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection due to immune modulation. - Concurrent use with other lysosomal enzymes: risk of additive infusion reactions.

Moderate Interactions (Monitor Closely): - Immunosuppressive agents (e.g., corticosteroids, azathioprine): may increase infection risk. - Other biologic therapies: potential for overlapping immunogenicity. - Anticoagulants: monitor bleeding parameters if infusion‑related thrombocytopenia occurs.